The relevance of Trabecular Bone Score (TBS) has been assessed in a large number of scientific publications worldwide. In addition, over thirty national and international clinical guidelines recommend TBS as a crucial tool for the assessment and management of osteoporosis.
This widespread interest for TBS supports our vision of elevating the standard of osteoporosis care around the world, by combining TBS with FRAX® and Bone Mineral Density (BMD) for a more comprehensive and insightful assessment of bone health.
All clinical papers including TBS are publicly available in PubMed, however you will find below a small selection of scientific articles documenting the use of TBS across different musculoskeletal disease areas.
Published in: Journal of Bone and Mineral Research
Date: 2013
Published in: Journal of Bone and Mineral Research
Date: 2011
medimaps group SA
Chemin du Champ-des-Filles 36A
1228 Plan-les-Ouates
Geneva, Switzerland
Medimaps Group USA LLC
1201N Market Street
Suite 111
Wilmington, DE 19801, United States
Medimaps Group has been certified by BSI to ISO 13485:2016 under certificate number MDR 799726. TBS iNsight is a trademark of Medimaps Group. TBS iNsight™ is cleared for sale in the U.S.
